赛隆药业(002898) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥68,594,554.99, an increase of 11.59% compared to the same period last year[6] - Net profit attributable to shareholders was ¥1,336,664.22, representing a significant increase of 107.11% year-on-year[6] - Basic and diluted earnings per share were both ¥0.0076, up 105.41% year-on-year[6] - Total operating revenue for Q3 2023 reached CNY 225,377,845.96, an increase of 16.9% compared to CNY 192,836,032.37 in Q3 2022[20] - Net profit for Q3 2023 was CNY 4,324,202.01, representing a significant increase of 154.5% from CNY 1,697,041.91 in Q3 2022[21] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.0246, compared to CNY 0.0096 in Q3 2022, marking an increase of 156.3%[22] Operating Costs and Expenses - The company reported a 44.02% increase in operating costs, totaling ¥110,560,644.11, primarily due to increased revenue[11] - Total operating costs for Q3 2023 were CNY 230,669,924.19, up from CNY 194,631,932.78 in the same period last year, reflecting a rise of 18.5%[20] - Research and development expenses for Q3 2023 totaled CNY 21,834,230.80, an increase of 23.1% from CNY 17,743,407.29 in Q3 2022[21] - Sales expenses decreased to CNY 53,142,350.87 in Q3 2023 from CNY 63,819,072.08 in Q3 2022, a reduction of 16.8%[21] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥2,832,502.63, an increase of 140.70%[6] - The net cash flow from operating activities for Q3 2023 was ¥2,832,502.63, a significant improvement from a net outflow of ¥6,959,283.72 in Q3 2022, indicating a recovery in operational efficiency[25] - Total cash inflow from investment activities reached ¥98,267,119.97, compared to ¥5,395,693.57 in the same period last year, reflecting increased investment recovery efforts[25] - The total cash and cash equivalents at the end of Q3 2023 were ¥14,875,363.10, down from ¥73,194,604.19 at the end of Q3 2022, indicating a tighter liquidity position[25] - Cash outflows for operating activities totaled ¥217,626,944.03, up from ¥189,295,701.69 in Q3 2022, highlighting increased operational expenditures[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥812,631,582.79, a decrease of 4.17% from the end of the previous year[6] - Total current assets as of September 30, 2023, amount to ¥231,367,027.07, a decrease from ¥254,357,080.25 at the beginning of the year[17] - The company’s non-current assets total ¥581,264,555.72, slightly down from ¥593,634,010.90[17] - The total liabilities as of Q3 2023 were CNY 281,958,688.65, down from CNY 321,642,399.02 in the previous year, a decrease of 12.3%[21] - Non-current liabilities increased to CNY 59,569,417.68 in Q3 2023 from CNY 25,190,991.95 in Q3 2022, a significant rise of 136.2%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,747[13] - The largest shareholder, Cai Nanguai, holds 51.15% of shares, totaling 90,016,937 shares, with 18,000,000 shares pledged[13] - Total equity attributable to shareholders was ¥530,672,894.14, a slight increase of 0.82% from the previous year[6] - Total equity attributable to shareholders of the parent company was CNY 530,672,894.14, slightly up from CNY 526,348,692.13 in Q3 2022, reflecting a growth of 0.6%[21] Inventory and Borrowings - The company’s inventory increased by 46.78% to ¥93,897,239.18, attributed to higher in-process and finished goods[10] - Short-term borrowings decreased to ¥70,000,000.00 from ¥100,063,081.04, a reduction of approximately 30%[17] - Long-term borrowings rose by 128.98% to ¥30,500,000.00, reflecting an increase in long-term loans during the reporting period[10] Accounting Standards - The company did not execute any new accounting standards adjustments for the first time in 2023, maintaining consistency in financial reporting[26]